WASHINGTON, DC-A report recently published in the New England Journal of Medicine suggests a vaccine could prevent staphylococcus infections, which are responsible for killing 40,000 Americans annually.
With 40% of staph strains resistant to antibiotics, scientists at the National Institutes of Health (NIH) have developed a vaccine to fight these potent pathogens. The immune response lasts only a few months, but researchers are reporting that out of 1,798 end stage kidney disease patients receiving dialysis, the vaccine protected 57% from infection. Such patients are at a heightened risk for developing an infection because they are constantly having their skin punctured for treatment.
The vaccine is slated to be used by patients facing major surgeries, such as heart surgery and joint replacement. Test participants have not reported any major side effects; the vaccine is expected to be on the market within two years.
Information from www.msnbc.com
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.